The clinical effectiveness and safety of intravenous unfractionated heparin following digital replantation and revascularization: A narrative systematic review
Research article published in Microsurgery (2022)
Abstract
BACKGROUND: Digital replants and revascularization (DRV) have been performed since the 1960s but there are no recognized standard peri-operative anticoagulation practices. A narrative systematic review of the clinical effectiveness and safety of therapeutic peri-operative unfractionated heparin following DRV was undertaken. METHODS: A review of the literature from 1985 to March 2022 was conducted using Medline, Embase, CINAHL and EBM reviews. Unfractionated heparin (UFH) use following DRV was compared to low-molecular weight heparin, other anticoagulants or no anticoagulation. Randomized trials, observational studies as well as guidelines were selected and independently screened. The Revised Cochrane risk-of-bias (RoB 2) tool and ROBINS-I were used to appraise risk of bias. RESULTS: While the search strategy identified 1490 references, only six studies met the inclusion criteria. Significant heterogeneity and the low methodological quality of the evidence precluded a meta-analysis. Among the four studies that documented the surgical success rate associated with the use of a therapeutic dose of UFH post DRV, only two reported improved clinical outcomes. Evidence of a higher complication rate related to UFH use was found in four studies. Low quality evidence suggests that a therapeutic dose of unfractionated heparin leads to a higher risk of complications when compared with heparin given as an intermittent bolus of unfractionated heparin or subcutaneous heparin, or prostaglandin E1 or no heparin. CONCLUSIONS: Current evidence suggests that IV UFH use following DRV has no significant impact on the success of the intervention. Heparin use may not be innocuous as some studies showed increased bleeding complications.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed research on safety and infection-control considerations relevant to leech therapy and anticoagulation. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta revisión sistemática narrativa analizó la literatura desde 1985 hasta marzo de 2022 en busca de estudios sobre la administración terapéutica de heparin no fraccionada (UFH) intravenosa tras el replante y la revascularización digital; encontró únicamente seis estudios elegibles de baja calidad metodológica (lo que impidió la realización de un meta-análisis) y concluyó que la UFH IV no mostró un impacto significativo en el éxito quirúrgico, mientras que cuatro estudios señalaron tasas más altas de complicaciones, incluyendo hemorragias. Esto es directamente relevante para la hirudoterapia debido a que las sanguijuelas medicinales son un complemento establecido para aliviar la congestión venosa en colgajos y dígitos replantados, y la evidencia débil y equívoca sobre el uso de heparin sistémica en este escenario exacto enmarca la pregunta clínica que a menudo se intenta resolver mediante la terapia con sanguijuelas: la descongestión local sin el riesgo de sangrado anticoagulante sistémico. Advertencia honesta: esta revisión resume una base de evidencia pequeña, heterogénea y de baja calidad, y no evalúa por sí misma la terapia con sanguijuelas, por lo que establece incertidumbre sobre la UFH sistémica en lugar de cualquier beneficio comparativo de la hirudoterapia.
Citación
The clinical effectiveness and safety of intravenous unfractionated heparin following digital replantation and revascularization: A narrative systematic review.
Deblois et al. · Microsurgery, 2022
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026